Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Down 53.5% in July

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the target of a significant decrease in short interest in July. As of July 31st, there was short interest totaling 3,860 shares, a decrease of 53.5% from the July 15th total of 8,310 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 25,979 shares, the days-to-cover ratio is currently 0.1 days.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Kiora Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC increased its position in shares of Kiora Pharmaceuticals by 71.0% in the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock valued at $42,000 after acquiring an additional 8,800 shares during the period. Two Sigma Investments LP purchased a new stake in shares of Kiora Pharmaceuticals during the third quarter worth about $33,000. Citadel Advisors LLC bought a new stake in shares of Kiora Pharmaceuticals in the third quarter worth about $125,000. DRW Securities LLC grew its stake in shares of Kiora Pharmaceuticals by 199.2% in the fourth quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock worth $217,000 after purchasing an additional 73,417 shares during the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Kiora Pharmaceuticals in the 4th quarter worth approximately $152,000. Institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Trading Down 2.0%

Shares of NASDAQ:KPRX traded down $0.05 on Monday, reaching $2.50. 7,208 shares of the company traded hands, compared to its average volume of 220,275. Kiora Pharmaceuticals has a 52 week low of $1.76 and a 52 week high of $2.99. The business’s 50-day simple moving average is $2.56 and its 200 day simple moving average is $2.38. The stock has a market capitalization of $11.05 million, a P/E ratio of -1.00 and a beta of -0.38.

Kiora Pharmaceuticals (NASDAQ:KPRX) last issued its earnings results on Friday, August 7th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.13.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.